18.01.2015 Views

CP01 Emergency Treatment of Anaphylactic Reactions - Devon ...

CP01 Emergency Treatment of Anaphylactic Reactions - Devon ...

CP01 Emergency Treatment of Anaphylactic Reactions - Devon ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Fig. 1<br />

A flow chart for the emergency treatment <strong>of</strong> an anaphylactic<br />

reaction (Appendix 1) will be located in the front pocket <strong>of</strong> the bag.<br />

The pack must be easily accessible in an emergency- under no<br />

circumstances will the pack be locked away in a drug cupboard or<br />

trolley.<br />

The ward manager / clinical team leader is responsible for ensuring<br />

that all clinical staff are aware <strong>of</strong> the agreed location <strong>of</strong> the<br />

Anaphylaxis Pack on their ward / unit and all new staff must be<br />

informed <strong>of</strong> this on their first day <strong>of</strong> employment.<br />

2.4 The Resuscitation Link Practitioner (or other designated registered nurse) will be<br />

responsible for checking and recording the expiry date <strong>of</strong> the emergency medication held on<br />

the ward and ensure the timely reordering <strong>of</strong> replacement stock.<br />

Good Practice Recommendation:<br />

Record the expiry date <strong>of</strong> all emergency medication held on the ward next to the medicine listed on<br />

the ward stock pr<strong>of</strong>ile (<strong>Emergency</strong> Medication section).<br />

The registered nurse completing the weekly medication stock order will check the expiry date on<br />

the pr<strong>of</strong>ile and re-order if the expiry date less than 2 weeks from the current date.<br />

2.5 <strong>Emergency</strong> medication will be re-ordered as necessary from the pharmacy department in<br />

accordance with Standard Operating Procedure MM27 (Ordering ward stock from pr<strong>of</strong>iles)<br />

3. Patient’s Own Medication (Adrenaline auto-injector devices)<br />

3.1 Auto-injectors devices (e.g. Epipen ® ) are prescribed on an individual basis, by a specialist in<br />

allergy, for self- administration by people who are at risk <strong>of</strong> an anaphylactic reaction.<br />

3.2 If a person on an inpatient unit experiences an anaphylactic reaction, intramuscular<br />

adrenaline (500micrograms) will be administered in accordance with this protocol (see<br />

section 2.1 and Appendix 1). However, if access to the emergency medication is delayed, it<br />

would be appropriate for a healthcare pr<strong>of</strong>essional to use the person’s own adrenaline autoinjector<br />

(NB this may deliver a dose <strong>of</strong> 300miccrograms or 500micrograms depending on the<br />

product prescribed), for the management <strong>of</strong> an anaphylactic reaction to ensure timely<br />

administration <strong>of</strong> treatment.<br />

3.3 For individuals prescribed an adrenaline auto-injector by a specialist or their GP, the product<br />

should be prescribed in the ‘when required’ section <strong>of</strong> the Trust inpatient prescription and<br />

administration chart to ensure clinicians are aware the person is prescribed, and usually<br />

carries, emergency medication for self- treatment <strong>of</strong> an anaphylactic reaction.<br />

3.4 Individuals prescribed an adrenaline auto-injector should carry this with them during periods<br />

<strong>of</strong> leave away from the unit and staff must also ensure that the person’s own adrenaline<br />

auto-injector device is returned to them at the time <strong>of</strong> discharge. (Refer to procedure MM08)<br />

4. Recognition and diagnosis <strong>of</strong> anaphylaxis<br />

4.1 When recognising (and treating) any acutely ill patient, a rational ABCDE approach must be<br />

followed (see 4.2) and life-threatening problems treated as they are recognised.<br />

4.2 A diagnosis <strong>of</strong> anaphylaxis is likely if a patient who is exposed to a trigger (allergen) also<br />

presents with the following;<br />

• Sudden onset and rapid progression <strong>of</strong> symptoms<br />

• Life-threatening Airway and/or Breathing and/or Circulation problems<br />

• Skin and/or mucosal changes (flushing, urticaria, angioedema)<br />

CP 01 - Protocol for the <strong>Emergency</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Anaphylactic</strong> <strong>Reactions</strong><br />

Approved by Drugs and Therapeutics Committee: March 2014<br />

Review Date: March 2016 Page 4 <strong>of</strong> 8

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!